Floatz logo

Therapeutic Asset Ratings

308 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
5-((R)-SEC-BUTYLAMINO)-N1-((1R,3S,5S)-8-(5-(CYCLOPROPANECARBONYL)PYRIDIN-2-YL)-8-AZABICYCLO(3.2.1)OCTAN-3-YL)-2-METHYLTEREPHTHALAMIDE
Melanoma
H. Lee Moffitt Cancer Center and Research InstituteP1CC (40)
bat4706
Melanoma
Bio-Thera SolutionsP1CC (40)
cft1946
Melanoma
C4 Therapeutics, Inc.P1CC (40)
Ganciclovir
Melanoma
Gene Surgery LLCP1CC (40)
gme751
Melanoma
SandozP1CC (40)
Stimotimagene Copolymerplasmid
Melanoma
Gene Surgery LLCP1CC (40)
PRT1419
Melanoma
Prelude TherapeuticsP1C (39)
ltt462
Melanoma
Novartis PharmaceuticalsP2C (37)
Acc-1898
Melanoma
AccSalus Biosciences, Inc.P1C (37)
ai-061
Melanoma
OncoC4, Inc.P1C (37)
autologous CD3+ enriched T lymphocytes obtained from peripheral blood mononuclear cells (PBMCs) by apheresis. The cells are transduced with a self-inactivating, non-replicating lentiviral vector encoding an enhanced-affinity T cell receptor (TCR) targeting the HLA-A*02:01-restricted MAGE-A4 peptide (GVYDGREHTV) alongside the CD8 alpha (CD8?) co-receptor. The expressed transgene comprises the coding sequence for the CD8? co-receptor, separated by a foot-and-mouth disease virus 2A self-cleaving peptide sequence from the coding sequence of the MAGE-A4 T-cell receptor alpha and beta chains that are separated from each other by a porcine teschovirus-1 2A self-cleaving peptide sequence, under control of the human elongation factor 1 alpha (EF-1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a tRNA primer binding site, a ? packaging signal, a truncated gag, a Rev response element (RRE) and a central polypurine tract (cPPT) sequence 5' to the transgene, and a polypurine tract (PPT) 3' to the transgene. The vector is pseudotyped with the vesicular stomatitis virus (VSV) G envelope glycoprotein. The CD3+ T lymphocytes are purified and activated using anti-CD3/anti-CD28 monoclonal antibody coated magnetic beads. The cells are then cultured in media containing interleukin 2 (IL-2), human AB serum and a protein kinase B (AKT inhibitor). The cells are CD3+ (> 80%), express the high affinity MAGE-A4 specific TCR and CD8? co-receptor (CD8? +TCR+; >16%) and are cytotoxic to MAGE-A4 expressing tumor cells
Melanoma
USWM CT, LLCP1C (37)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
Melanoma
USWM CT, LLCP1C (37)
Autologous Total Tumor Mrna Loaded Dotap Liposome Vaccine
Melanoma
University of FloridaP1C (37)
b7-h3 car t cells
Melanoma
St. Jude Children's Research HospitalP1C (37)
ba1302
Melanoma
Shandong Boan Biotechnology Co., LtdP1C (37)
Bdc-3042
Melanoma
Bolt Biotherapeutics, Inc.P1C (37)
Belvarafenib
Melanoma
Genentech, Inc.P1C (37)
bi 3810944
Melanoma
Boehringer IngelheimP1C (37)
bi 765063
Melanoma
Boehringer IngelheimP1C (37)
bi 770371
Melanoma
Boehringer IngelheimP1C (37)
bmc128
Melanoma
Biomica Ltd.P1C (37)
Claturafenib
Melanoma
PfizerP1C (37)
Dcc-3084
Melanoma
Deciphera Pharmaceuticals, LLCP1C (37)
Definity
Melanoma
Sunnybrook Health Sciences CentreP1C (37)
dky709
Melanoma
Novartis PharmaceuticalsP1C (37)
Showing 201 to 225 of 308 assets
PreviousPage 9 of 13Next